quantisnow
FeedTopReportsPricing
⌘K
Live feed
07:41:36·690d
NEWSRelease
Fresh Tracks Therapeutics Inc. logo
Grove Collaborative Holdings Inc. logo
Monopar Therapeutics Inc. logo

Monopar Therapeutics And 2 Other Stocks Under $2 Insiders Are Buying

FRTX· Fresh Tracks Therapeutics Inc.GROV· Grove Collaborative Holdings Inc.MNPR· Monopar Therapeutics Inc.
Health CareConsumer Discretionary
Original source

Companies

  • FRTX
    Fresh Tracks Therapeutics Inc.
    Health Care
  • GROV
    Grove Collaborative Holdings Inc.
    Consumer Discretionary
  • MNPR
    Monopar Therapeutics Inc.
    Health Care

Recent analyst ratings

  • Jan 9MNPRUpdateMorgan Stanley$115.00
  • Nov 14MNPRUpdateRaymond James-
  • Nov 10MNPRUpdateLeerink Partners$115.00
  • Oct 13MNPRUpdateBarclays$125.00
  • Sep 9MNPRUpdateBTIG Research$87.00
  • Sep 3MNPRUpdateOppenheimer$77.00

Related

  • PR18h
    Grove to Report First Quarter 2026 Financial Results on May 7, 2026
  • SEC4d
    Monopar Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
  • PR4d
    Monopar Presents Phase 3 Data Showing Greater Neurologic Benefit with ALXN1840 vs SoC in Wilson Disease Patients with Neurologic Symptoms at AAN 2026
  • INSIDER15d
    SEC Form 3 filed by new insider Davey Keith M
  • INSIDER15d
    SEC Form 3 filed by new insider Giesler Gary Scott
  • INSIDER21d
    SEC Form 4 filed by Robinson Chandler
  • INSIDER21d
    SEC Form 4 filed by Cittadine Andrew
  • SEC22d
    Amendment: SEC Form 10-K/A filed by Monopar Therapeutics Inc.
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022